Multidisciplinary Association for Psychedelic Studies
12
2
2
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
8.3%
1 terminated/withdrawn out of 12 trials
88.9%
+2.4% vs industry average
8%
1 trials in Phase 3/4
38%
3 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Epigenetics and MDMA-Assisted Psychotherapy for PTSD
Role: collaborator
MDMA for Co-occurring PTSD and OUD After Childbirth
Role: collaborator
MDMA-assisted Therapy for Fibromyalgia
Role: collaborator
Inhaled Cannabis for Treatment of PTSD
Role: lead
Social Anxiety MDMA-Assisted Therapy Investigation
Role: collaborator
MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD
Role: collaborator
Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study
Role: collaborator
Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification
Role: collaborator
A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)
Role: collaborator
Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma
Role: lead
Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety
Role: lead
Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD
Role: lead
All 12 trials loaded